Logo

Moderna to Seek the FDA and EMA's EUA for mRNA-1273 and Shows 100% Efficacy in P-III COVE-Study

Share this

Moderna to Seek the FDA and EMA's EUA for mRNA-1273 and Shows 100% Efficacy in P-III COVE-Study

Shots:

  • The P-III COVE study demonstrated 94.1% efficacy against COVID-19 and 100% efficacy against severe COVID-19. The vaccine was well tolerated with no serious safety concerns identified to date
  • Moderna plans to submit an EUA to the FDA & an application for CMA with the EMA and to progress with the rolling reviews- which have already been initiated with international regulatory agencies
  • The FDA has told Company to expect VRBPAC meeting for mRNA-1273 on Dec 17- 2020. The Company will submit data from the P-III COVE study to a peer-reviewed publication

 ­ Ref: Moderna | Image: Moderna

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions